Skip to main content
SpringerLink
Log in

CD1-Restricted T Cells and Tumor Immunity

  • Chapter
Book cover T Cell Activation by CD1 and Lipid Antigens

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 314))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what’s in a name? Nat Rev Immunol 4:231–237

    Article  PubMed  CAS  Google Scholar 

  2. Koseki H, Imai K, Nakayama F, Sado T, Moriwaki K, Taniguchi M (1990) Homogenous junctional sequence of the V14+ T-cell antigen receptor alpha chain expanded in unprimed mice. Proc Natl Acad Sci U S A 87:5248–5252

    Article  PubMed  CAS  Google Scholar 

  3. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR (1995) CD1 recognition by mouse NK1+ T lymphocytes. Science 268:863–865

    Article  PubMed  CAS  Google Scholar 

  4. Smiley ST, Kaplan MH, Grusby MJ (1997) Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275:977–979

    Article  PubMed  CAS  Google Scholar 

  5. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR (1997) Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 6:459–467

    Article  PubMed  CAS  Google Scholar 

  6. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L (1997) CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6:469–477

    Article  PubMed  CAS  Google Scholar 

  7. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E et al (1997) CD1d-restricted and TCR-mediated activation of valpha14. NKT cells by glycosylceramides. Science 278:1626–1629

    Article  PubMed  CAS  Google Scholar 

  8. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M (2000) Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 192:741–754

    Article  PubMed  CAS  Google Scholar 

  9. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A (2000) In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 191:1895–1903

    Article  PubMed  CAS  Google Scholar 

  10. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M (1998) CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188:1521–1528

    Article  PubMed  CAS  Google Scholar 

  11. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198:173–181

    Article  PubMed  CAS  Google Scholar 

  12. Rauch J, Gumperz J, Robinson C, Skold M, Roy C, Young DC, Lafleur M, Moody DB, Brenner MB, Costello CE et al (2003) Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem 278:47508–47515

    Article  PubMed  CAS  Google Scholar 

  13. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr, Murphy WJ, Wiltrout RH (2004) Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 172:943–953

    PubMed  CAS  Google Scholar 

  14. Parekh VV, Singh AK, Wilson MT, Olivares-Villagomez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L et al (2004) Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha-and beta-anomeric glycolipids. J Immunol 173:3693–3706

    PubMed  CAS  Google Scholar 

  15. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu YP, Yamashita T et al (2004) Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786–1789

    Article  PubMed  CAS  Google Scholar 

  16. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C 3rd, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N et al (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525–529

    Article  PubMed  CAS  Google Scholar 

  17. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong CH, Kronenberg M (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520–525

    Article  PubMed  CAS  Google Scholar 

  18. Chiu YH, Jayawardena J, Weiss A, Lee D, Park SH, Dautry-Varsat A, Bendelac A (1999) Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 189:103–110

    Article  PubMed  CAS  Google Scholar 

  19. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661–668

    Article  PubMed  CAS  Google Scholar 

  20. Crowe NY, Smyth MJ, Godfrey DI (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119–127

    Article  PubMed  CAS  Google Scholar 

  21. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB et al (2000) Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211–221

    Article  PubMed  CAS  Google Scholar 

  22. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4:1230–1237

    Article  PubMed  CAS  Google Scholar 

  23. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202:1279–1288

    Article  PubMed  CAS  Google Scholar 

  24. Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakayama T et al (2003) CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 100:10902–10906

    Article  PubMed  CAS  Google Scholar 

  25. Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M et al (2005) Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 102:9253–9257

    Article  PubMed  CAS  Google Scholar 

  26. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H (2003) Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520

    PubMed  CAS  Google Scholar 

  27. Jiang S, Game DS, Davies D, Lombardi G, Lechler RI (2005) Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+regulatory T cells? Eur J Immunol 35:1193–1200

    Article  PubMed  CAS  Google Scholar 

  28. Crespo FA, Sun X, Cripps JG, Fernandez-Botran R (2006) The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol 79:586–595

    Article  PubMed  CAS  Google Scholar 

  29. Jaffee EM (1999) Immunotherapy of cancer. Ann N Y Acad Sci 886:67–72

    Article  PubMed  CAS  Google Scholar 

  30. Eager R, Nemunaitis J (2005) GM-CSF gene-transduced tumor vaccines. Mol Ther 12:18–27

    Article  PubMed  CAS  Google Scholar 

  31. Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N, Luster AD, Blumberg RS, Taniguchi M, Balk SP et al (2003) CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A 100:8874–8879

    Article  PubMed  CAS  Google Scholar 

  32. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y (1995) KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7:529–534

    PubMed  CAS  Google Scholar 

  33. Yamaguchi Y, Motoki K, Ueno H, Maeda K, Kobayashi E, Inoue H, Fukushima H, Koezuka Y (1996) Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol Res 8:399–407

    PubMed  CAS  Google Scholar 

  34. Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, Shimosaka A, Koezuka Y (1998) Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide KRN7000. Cancer Res 58:1202–1207

    PubMed  CAS  Google Scholar 

  35. Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, Tsuyuki S, Inamoto T, Koezuka Y (1998) Antitumor activity of alpha-galactosylceramide KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 10:561–568

    PubMed  CAS  Google Scholar 

  36. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI (2002) Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99:1259–1266

    Article  PubMed  CAS  Google Scholar 

  37. Hayakawa Y, Rovero S, Forni G, Smyth MJ (2003) Alpha-galactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 100:9464–9469

    Article  PubMed  CAS  Google Scholar 

  38. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K (2001) Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31:1720–1727

    Article  PubMed  CAS  Google Scholar 

  39. Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, Taniguchi M, Hayakawa K, Kronenberg M (1998) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NKT lymphocytes. J Immunol 161:3271–3281

    PubMed  CAS  Google Scholar 

  40. Yang YF, Tomura M, Ono S, Hamaoka T, Fujiwara H (2000) Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. Int Immunol 12:1669–1675

    Article  PubMed  CAS  Google Scholar 

  41. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199:1607–1618

    Article  PubMed  CAS  Google Scholar 

  42. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L et al (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189:1121–1128

    Article  PubMed  CAS  Google Scholar 

  43. Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H (2000) Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 6:3380–3387

    PubMed  CAS  Google Scholar 

  44. Tomura M, Yu WG, Ahn HJ, Yamashita M, Yang YF, Ono S, Hamaoka T, Kawano T, Taniguchi M, Koezuka Y et al (1999) A novel function of Valpha14+ CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 163:93–101

    PubMed  CAS  Google Scholar 

  45. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8. T cell immunity to a coadministered protein. J Exp Med 198:267–279

    Article  PubMed  CAS  Google Scholar 

  46. Osada T, Morse MA, Lyerly HK, Clay TM (2005) Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol 17:1143–1155

    Article  PubMed  CAS  Google Scholar 

  47. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:4647–4650

    PubMed  CAS  Google Scholar 

  48. Eberl G, MacDonald HR (2000) Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30:985–992

    Article  PubMed  CAS  Google Scholar 

  49. Eberl G, Brawand P, MacDonald HR (2000) Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NKT or T cell activation. J Immunol 165:4305–4311

    PubMed  CAS  Google Scholar 

  50. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T et al (2000) The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 12:987–994

    Article  PubMed  CAS  Google Scholar 

  51. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195:617–624

    Article  PubMed  CAS  Google Scholar 

  52. Nakagawa R, Inui T, Nagafune I, Tazunoki Y, Motoki K, Yamauchi A, Hirashima M, Habu Y, Nakashima H, Seki S (2004) Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide. J Immunol 172:6550–6557

    PubMed  CAS  Google Scholar 

  53. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I (2002) IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100:1728–1733

    PubMed  CAS  Google Scholar 

  54. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661–670

    Article  PubMed  CAS  Google Scholar 

  55. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166:6578–6584

    PubMed  CAS  Google Scholar 

  56. Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3:867–874

    Article  PubMed  CAS  Google Scholar 

  57. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, Lew AM, Bouillet P, Strasser A, Smyth MJ, Godfrey DI (2005) NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175:3092–3101

    PubMed  CAS  Google Scholar 

  58. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115:2572–2583

    Article  PubMed  CAS  Google Scholar 

  59. Fujii S, Shimizu K, Steinman RM, Dhodapkar MV (2003) Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 272:147–159

    Article  PubMed  CAS  Google Scholar 

  60. Van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, Pinedo HM, Scheper RJ, Giaccone G (2001) Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 247:61–72

    Article  PubMed  Google Scholar 

  61. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S (2005) Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 174:4696–4705

    PubMed  CAS  Google Scholar 

  62. Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M (2005) Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci U S A 102:1127–1132

    Article  PubMed  CAS  Google Scholar 

  63. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M (1999) Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163:2387–2391

    PubMed  CAS  Google Scholar 

  64. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y (2005) Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201:1973–1985

    Article  PubMed  CAS  Google Scholar 

  65. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14. NKT cells in IL-12-mediated rejection of tumors. Science 278:1623–1626

    Article  PubMed  CAS  Google Scholar 

  66. Takeda K, Seki S, Ogasawara K, Anzai R, Hashimoto W, Sugiura K, Takahashi M, Satoh M, Kumagai K (1996) Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 156:3366–3373

    PubMed  CAS  Google Scholar 

  67. Kobayashi T, Shiiba K, Satoh M, Hashimoto W, Mizoi T, Matsuno S, Takeda K (2002) Interleukin-12 administration is more effective for preventing metastasis than for inhibiting primary established tumors in a murine model of spontaneous hepatic metastasis. Surg Today 32:236–242

    Article  PubMed  CAS  Google Scholar 

  68. Shin T, Nakayama T, Akutsu Y, Motohashi S, Shibata Y, Harada M, Kamada N, Shimizu C, Shimizu E, Saito T et al (2001) Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14. NKT cells. Int J Cancer 91:523–528

    Article  PubMed  CAS  Google Scholar 

  69. Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665–2670

    PubMed  CAS  Google Scholar 

  70. Takeda K, Hayakawa Y, Atsuta M, Hong S, Van Kaer L, Kobayashi K, Ito M, Yagita H, Okumura K (2000) Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 12:909–914

    Article  PubMed  CAS  Google Scholar 

  71. Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L, Schneider E, Dy M, Herbelin A (2001) IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol 166:945–951

    PubMed  CAS  Google Scholar 

  72. Baxevanis CN, Gritzapis AD, Papamichail M (2003) In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 171:2953–2959

    PubMed  CAS  Google Scholar 

  73. Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger HM, Burman AC, Olver SD, Kienzle N et al (2005) NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115:3093–3103

    Article  PubMed  CAS  Google Scholar 

  74. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR (1999) Tissue-specific segregation of CD1d-dependent and CD1d-independent NKT cells. J Immunol 162:6410–6419

    PubMed  CAS  Google Scholar 

  75. Hammond KJ, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, Smyth MJ, van Driel IR, Scollay R, Baxter AG et al (1999) NKT cells are pheno-typically and functionally diverse. Eur J Immunol 29:3768–3781

    Article  PubMed  CAS  Google Scholar 

  76. Gumperz JE, Miyake S, Yamamura T, Brenner MB (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195:625–636

    Article  PubMed  CAS  Google Scholar 

  77. Lee PT, Benlagha K, Teyton L, Bendelac A (2002) Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195:637–641

    Article  PubMed  CAS  Google Scholar 

  78. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI (2005) Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 35:1399–1407

    Article  PubMed  CAS  Google Scholar 

  79. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, Juji T, Hirai H (2002) Cutting edge: analysis of human V alpha 24+CD8+ NKT cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168:3140–3144

    PubMed  CAS  Google Scholar 

  80. Rogers PR, Matsumoto A, Naidenko O, Kronenberg M, Mikayama T, Kato S (2004) Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN(7000). J Immunol Methods 285:197–214

    Article  PubMed  CAS  Google Scholar 

  81. Lin H, Nieda M, Nicol AJ (2004) Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 34:2664–2671

    Article  PubMed  CAS  Google Scholar 

  82. Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O’Farrelly C, Doherty DG (2003) NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 171:1775–1779

    PubMed  CAS  Google Scholar 

  83. Wang ZY, Kusam S, Munugalavadla V, Kapur R, Brutkiewicz RR, Dent AL (2006) Regulation of Th2 cytokine expression in NKT cells: unconventional use of Stat6, GATA-3, and NFAT2. J Immunol 176:880–888

    PubMed  CAS  Google Scholar 

  84. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, Locksley RM, Kronenberg M (2003) Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A 100:8395–8400

    Article  PubMed  CAS  Google Scholar 

  85. Maeda M, Lohwasser S, Yamamura T, Takei F (2001) Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line. J Immunol 167:4180–4186

    PubMed  CAS  Google Scholar 

  86. Kim CH, Butcher EC, Johnston B (2002) Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol 23:516–519

    Article  PubMed  CAS  Google Scholar 

  87. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Strominger JL, Brenner MB, Gumperz JE, Wilson SB et al (2003) CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 171:2571–2580

    PubMed  CAS  Google Scholar 

  88. Johnston B, Kim CH, Soler D, Emoto M, Butcher EC (2003) Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 171:2960–2969

    PubMed  CAS  Google Scholar 

  89. Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, Nakatsura T, Nishimura Y, Senju S (2005) Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci 96:889–896

    Article  PubMed  CAS  Google Scholar 

  90. Lin H, Nieda M, Rozenkov V, Nicol AJ (2006) Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8. T cells NK cells, and B cells. Exp Hematol 34:289–295

    Article  PubMed  CAS  Google Scholar 

  91. Van Kaer L (2005) Alpha-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 5:31–42

    Article  PubMed  CAS  Google Scholar 

  92. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S, Iizasa T, Endo H et al (1999) Antitumor cytotoxicity mediated by ligand-activated human V alpha24. NKT cells. Cancer Res 59:5102–5105

    PubMed  CAS  Google Scholar 

  93. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA (2001) Loss of IFN-gamma production by invariant NKT cells in advanced cancer. J Immunol 167:4046–4050

    PubMed  CAS  Google Scholar 

  94. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17:1068–1077

    Article  PubMed  CAS  Google Scholar 

  95. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, Varese P, Ciccone E, Grossi CE (2004) CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 109:402–411

    Article  PubMed  CAS  Google Scholar 

  96. Takahashi T, Haraguchi K, Chiba S, Yasukawa M, Shibata Y, Hirai H (2003) Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Br J Haematol 122:231–239

    Article  PubMed  Google Scholar 

  97. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667–1676

    Article  PubMed  CAS  Google Scholar 

  98. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M (2002) Preserved IFN-alpha production of circulating Valpha24. NKT cells in primary lung cancer patients. Int J Cancer 102:159–165

    Article  PubMed  CAS  Google Scholar 

  99. Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M (2004) The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 65:1377–1388

    Article  PubMed  CAS  Google Scholar 

  100. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, Imamura M (2005) Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11:7322–7327

    Article  PubMed  CAS  Google Scholar 

  101. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ et al (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709

    PubMed  CAS  Google Scholar 

  102. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ (2004) Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383–389

    Article  PubMed  CAS  Google Scholar 

  103. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11:1910–1917

    Article  PubMed  CAS  Google Scholar 

  104. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R et al (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503–1517

    Article  PubMed  CAS  Google Scholar 

  105. Schmieg J, Yang G, Franck RW, Tsuji M (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 198:1631–1641

    Article  PubMed  CAS  Google Scholar 

  106. Miyamoto K, Miyake S, Yamamura T (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531–534

    Article  PubMed  CAS  Google Scholar 

  107. Oki S, Chiba A, Yamamura T, Miyake S (2004) The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113:1631–1640

    Article  PubMed  CAS  Google Scholar 

  108. Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS et al (2003) Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol 171:4539–4551

    PubMed  CAS  Google Scholar 

  109. Nakui M, Ohta A, Sekimoto M, Sato M, Iwakabe K, Yahata T, Kitamura H, Koda T, Kawano T, Makuuchi H et al (2000) Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin Exp Metastasis 18:147–153

    Article  PubMed  CAS  Google Scholar 

  110. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, Wainstok R, Bai XF, Liu Y, Steinman RM (2005) Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202:1507–1516

    Article  PubMed  CAS  Google Scholar 

  111. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171:5140–5147

    PubMed  CAS  Google Scholar 

  112. Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163:184–193

    PubMed  CAS  Google Scholar 

  113. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515–520

    Article  PubMed  CAS  Google Scholar 

  114. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B et al (2003) Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741–1752

    Article  PubMed  CAS  Google Scholar 

  115. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA (2005) Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 114:80–87

    Article  PubMed  CAS  Google Scholar 

  116. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK (2002) Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 169:5796–5804

    PubMed  CAS  Google Scholar 

  117. Ostrand-Rosenberg S, Grusby MJ, Clements VK (2000) Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165:6015–6019

    PubMed  CAS  Google Scholar 

  118. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65:11743–11751

    Article  PubMed  CAS  Google Scholar 

  119. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA (2005) A nonclassical non-Valpha14Jalpha18. CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202:1627–1633

    Article  PubMed  CAS  Google Scholar 

  120. Sfondrini L, Besusso D, Zoia MT, Rodolfo M, Invernizzi AM, Taniguchi M, Nakayama T, Colombo MP, Menard S, Balsari A (2002) Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 169:151–158

    PubMed  CAS  Google Scholar 

  121. Behar SM, Podrebarac TA, Roy CJ, Wang CR, Brenner MB (1999) Diverse TCRs recognize murine CD1. J Immunol 162:161–167

    PubMed  CAS  Google Scholar 

  122. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A (2001) The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 193:893–904

    Article  PubMed  CAS  Google Scholar 

  123. Chiu YH, Park SH, Benlagha K, Forestier C, Jayawardena-Wolf J, Savage PB, Teyton L, Bendelac A (2002) Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol 3:55–60

    Article  PubMed  CAS  Google Scholar 

  124. Duarte N, Stenstrom M, Campino S, Bergman ML, Lundholm M, Holmberg D, Cardell SL (2004) Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 173:3112–3118

    PubMed  CAS  Google Scholar 

  125. Exley MA, He Q, Cheng O, Wang RJ, Cheney CP, Balk SP, Koziel MJ (2002) Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol 168:1519–1523

    PubMed  CAS  Google Scholar 

  126. Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP (2001) A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 167:5531–5534

    PubMed  CAS  Google Scholar 

  127. Yue SC, Shaulov A, Wang R, Balk SP, Exley MA (2005) CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A 102:11811–11816

    Article  PubMed  CAS  Google Scholar 

  128. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS (1999) Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci U S A 96:13938–13943

    Article  PubMed  CAS  Google Scholar 

  129. Chang CS, Brossay L, Kronenberg M, Kane KP (1999) The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. J Exp Med 189:483–491

    Article  PubMed  CAS  Google Scholar 

  130. Huang MM, Borszcz P, Sidobre S, Kronenberg M, Kane KP (2004) CD1d1 displayed on cell size beads identifies and enriches an NK cell population negatively regulated by CD1d1. J Immunol 172:5304–5312

    PubMed  CAS  Google Scholar 

  131. Maeda M, Carpenito C, Russell RC, Dasanjh J, Veinotte LL, Ohta H, Yamamura T, Tan R, Takei F (2005) Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J Immunol 175:4426–4432

    PubMed  CAS  Google Scholar 

  132. Hayakawa Y, Godfrey DI, Smyth MJ (2004) Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem 11:241–252

    Article  PubMed  CAS  Google Scholar 

  133. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI (2002) NKT cells—conductors of tumor immunity? Curr Opin Immunol 14:165–171

    Article  PubMed  CAS  Google Scholar 

  134. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP et al (2005) Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201:139–148

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, University of Melbourne, 3010, Parkville, Victoria, Australia

    J. M. C. Coquet & D. I. Godfrey

  2. Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria, Australia

    J. B. Swann & M. J. Smyth

Authors
  1. J. B. Swann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. C. Coquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. J. Smyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. I. Godfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, Smith 514 1 Jimmy Fund Way, Boston, MA, 02115, USA

    D. Branch Moody M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Swann, J.B., Coquet, J.M.C., Smyth, M.J., Godfrey, D.I. (2007). CD1-Restricted T Cells and Tumor Immunity. In: Moody, D.B. (eds) T Cell Activation by CD1 and Lipid Antigens. Current Topics in Microbiology and Immunology, vol 314. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69511-0_12

Download citation

Publish with us

Policies and ethics

Search

Navigation